TriangleNCT03687125 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- true
- limitations And Caveats
- description
- Study was early terminated during Phase 1 due to sponsor decision on 17 April 2019 (adverse events limited administration of higher doses required to achieve myeloablative conditioning necessary in this population). Hence, no participants were enrolled in Phase 2 and efficacy analysis were not performed in the both Phase 1 and 2.
- point Of Contact
- terry.nichols@mundipharma-rd.eu
- organization
- Mundipharma Research Limited
- phone
- (0044)1223424444
- title
- Terry Nichols
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- true
- limitations And Caveats
- description
- Study was early terminated during Phase 1 due to sponsor decision on 17 April 2019 (adverse events limited administration of higher doses required to achieve myeloablative conditioning necessary in this population). Hence, no participants were enrolled in Phase 2 and efficacy analysis were not performed in the both Phase 1 and 2.
- point Of Contact
- terry.nichols@mundipharma-rd.eu
- organization
- Mundipharma Research Limited
- phone
- (0044)1223424444
- title
- Terry Nichols
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice